革兰阴性菌感染的新型治疗药物:奇迹重现还是虚假曙光?
本综述通过MEDLINE检索及临床试验注册库,汇总了已获批或完成后期临床试验的抗耐药革兰阴性菌新药的疗效、抗菌谱及耐药发展证据。新型β-内酰胺/β-内酰胺酶抑制剂组合、头孢地尔、普拉佐米星等为多重耐药菌提供了重要选择,但部分药物临床疗效的确证数据尚缺,且早期耐药报道令人关注。
要点
- 多黏菌素似已被新药取代,不再作为产KPC肺炎克雷伯菌的一线治疗。
- 头孢地尔及头孢他啶/阿维巴坦/氨曲南是产金属β-内酰胺酶菌的潜力选择。
- 口服药物及抗鲍曼不动杆菌药物在临床开发中代表性不足。
核心结论
- 抗多重耐药革兰阴性菌新药的研发为临床提供了重要治疗选择,但部分药物缺乏确证的临床疗效数据,且早期耐药报道值得关注。
研究设计与样本
- 综述性研究,通过MEDLINE数据库检索已发表文献,并借助clinicaltrials.gov注册库识别相关临床试验,补充近期国际会议摘要及制药公司数据。
主要发现
- 报告了头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦、亚胺培南/西司他丁/瑞来巴坦、美罗培南/法硼巴坦、氨曲南/阿维巴坦、头孢地尔、普拉佐米星和依拉环素的作用机制、抗菌谱、临床疗效及耐药发展数据。
- 多黏菌素似已被新药取代作为产KPC肺炎克雷伯菌的一线治疗。
- 头孢地尔及头孢他啶/阿维巴坦/氨曲南是产金属β-内酰胺酶菌的潜力选择,头孢地尔和头孢洛扎/他唑巴坦对多重耐药铜绿假单胞菌有潜力,但确证临床疗效的数据尚缺。
- 新药上市使用后早期出现耐药报道令人关注。
- 口服选项及对鲍曼不动杆菌有效的药物在临床开发中代表性不足。
临床怎么用
- 对于产KPC肺炎克雷伯菌感染,可考虑以新药替代多黏菌素作为一线治疗。
- 产金属β-内酰胺酶菌感染可考虑头孢地尔或头孢他啶/阿维巴坦/氨曲南,但需注意临床疗效确证数据尚不充分。
- 多重耐药铜绿假单胞菌感染可考虑头孢地尔或头孢洛扎/他唑巴坦。
- 使用新药时需关注早期耐药的发生。
局限性
- 头孢地尔和头孢洛扎/他唑巴坦等对多重耐药铜绿假单胞菌的确证临床疗效数据尚缺。
- 口服药物及抗鲍曼不动杆菌药物在临床开发中代表性不足。
- 新药上市后早期耐药报道引发担忧。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antibiotic resistance in Gram-negative resistance has developed without a commensurate response in the successful development of antibiotic agents, though recent progress has been made. AIMS: This review aims to provide a summary of the existing evidence on efficacy, spectrum of activity and the development of resistance of new agents that have been licensed or have completed advanced clinical trials and that possess activity against resistant Gram-negative organisms. SOURCES: A review of the published literature via MEDLINE database was performed. Relevant clinical trials were identified with the aid of the clinicaltrials.gov registry. Further data were ascertained from review of abstracts from recent international meetings and pharmaceutical companies. CONTENT: Data on the mechanism of action, microbiological spectrum, clinical efficacy and development of resistance are reported for new agents that have activity against Gram-negative organisms. This includes the β-lactam/β-lactamase inhibitor combinations ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/cilastatin/relebactam, meropenem/vaborbactam and aztreonam/avibactam; cefiderocol, a siderophore cephalosporin; plazomicin and eravacycline. IMPLICATIONS: The development of new agents with activity against multidrug-resistant Gram-negative pathogens has provided important therapeutic options for clinicians. Polymyxins appear to have been supplanted by new agents as first-line therapy for Klebsiella pneumoniae carbapenemase producers. Cefiderocol and ceftazidime/avibactam/aztreonam are promising options for metallo-β-lactamase producers, and cefiderocol and ceftolozane/tazobactam for multiply resistant Pseudomonas aeruginosa, but definitive data showing clinical efficacy is as yet lacking. Reports of the development of resistance early after the release and use of new agents is of concern. Orally administered options and agents active effective against Acinetobacter baumannii are under-represented in clinical development.
引用
- Wright H, Bonomo RA, Paterson DL, et al. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect. 2017. PMID: 28893690. doi:10.1016/j.cmi.2017.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。